NGI‑189 是一种选择性 OST‑A 抑制剂,通过抑制 OST 复合物的 STT3A 催化亚基降低靶标糖蛋白的 N-糖基化水平,阻断致癌信号与旁路信号传导,降低 EGFR、AKT、p70S6K 和 S6RP 的磷酸化水平,并诱导周期阻滞与凋亡 (apoptosis),在非小细胞肺癌 (NSCLC) 异种移植模型中显著抑制肿瘤生长并诱导肿瘤消退,可用于 EGFR 突变型非小细胞肺癌的相关研究。
产品编号: MS-I36769 纯度: 99.29% CAS No.: 2763063-26-7 分子式: C22H30N4O4S2 分子量: 478.63
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
10mM * 1mL in DMSO
询价
3-5 天
1mg
询价
3-5 天
5mg
询价
3-5 天
10mg
询价
询价
25mg
询价
询价
50mg
询价
询价
100mg
询价
询价

产品描述

NGI‑189 是一种选择性 OST‑A 抑制剂,通过抑制 OST 复合物的 STT3A 催化亚基降低靶标糖蛋白的 N-糖基化水平,阻断致癌信号与旁路信号传导,降低 EGFR、AKT、p70S6K 和 S6RP 的磷酸化水平,并诱导周期阻滞与凋亡 (apoptosis),在非小细胞肺癌 (NSCLC) 异种移植模型中显著抑制肿瘤生长并诱导肿瘤消退,可用于 EGFR 突变型非小细胞肺癌的相关研究。

生物实验数据

生物活性 NGI‑189 is a selective OST‑A inhibitor that inhibits the STT3A catalytic subunit of the OST complex to reduce N‑glycosylation of target glycoproteins, blocks oncogenic and bypass signaling, decreases phosphorylation of EGFR, AKT, p70S6K, and S6RP, and induces cell cycle arrest and apoptosis, significantly inhibiting tumor growth and inducing tumor regression in non‑small cell lung cancer (NSCLC) xenograft models, and can be used for research on EGFR‑mutant non‑small cell lung cancer.
IC50 & Target

Akt

 

EGFRL858R/T790M

 

EGFR

 

Bim

 

体外研究
(In Vitro)

NGI-189 (0.09 μM) 可强效抑制 ER-LucT 报告细胞中的 N-糖基化修饰,其 IC50 为 0.09 μM。
NGI-189 (5 μM; 5 days) 可将亲本 PC9 EGFR 突变型 NSCLC 细胞的增殖抑制约 70%,而在表达不依赖 N-糖基化的 EGFR 的 PC9-CD8-EGFR-CL 细胞中,该抑制作用被显著逆转。
NGI-189 (0-25 μM; 24 h) 可优先抑制 HEK293 野生型、STT3A 敲除及 STT3B 敲除细胞中的 OST-A 复合物,以剂量依赖方式降低 EGFR 和 Halo3N 的 N-糖基化水平,且仅在 STT3B KO 细胞中可实现 OST-A 依赖性糖基化的完全抑制。
NGI-189 (10 μM; 24 h) 可降低 Osimertinib (MS-Q22788) 耐药型 H1975-OR 细胞和 Gefitinib (MS-R64130) 耐药型 HCC827-GR 非小细胞肺癌细胞中旁路 PTK7、MET 的 N-糖基化水平,并抑制下游 STAT3 信号通路。
NGI‑189 (5 μM) 可降低亲本 PC9 EGFR 突变型非小细胞肺癌 (NSCLC) 细胞的克隆形成存活率;同时它还能显著降低 H3255、HCC‑4006 和 HCC‑2935 EGFR 突变型 NSCLC 细胞的克隆形成存活率。
NGI-189 (5 μM; 24 h) 可抑制 EGFR 及其下游 AKT/p70 S6K/S6RP 信号通路,并在 H3255、HCC-4006 和 HCC-2935 这三种 EGFR 突变型非小细胞肺癌 (NSCLC) 细胞中诱导促凋亡蛋白 Bim 的表达。
NGI-189 (5 μM; 24 h) 可诱导 PC9 EGFR 突变型 NSCLC 细胞发生 G1 期细胞周期阻滞,并在 H3255 和 HCC-2935 EGFR 突变型 NSCLC 细胞中触发 G1 期阻滞,同时伴随显著的细胞死亡 (亚 G1 细胞群)。

Western Blot Analysis

Cell Line: HEK293 wild-type, STT3A knockout (KO), and STT3B KO cells expressing Halo3N glycoprotein
Concentration: 0 μM, 0.1 μM, 1 μM, 5 μM, 10 μM, 25 μM
Incubation Time: 24 h
Result: Reduced the molecular weight of EGFR and Halo3N in wild-type HEK293 cells at all tested concentrations, indicating reduced N-glycosylation.
Showed weaker inhibition of N-glycosylation in STT3A KO cells, while showed potent inhibition in STT3B KO cells, demonstrating preferential activity against the OST-A (STT3A-containing) complex.
Achieved complete inhibition of OST-A dependent N-glycosylation in STT3B KO cells at doses >10 μM, but could not achieve complete N-glycosylation inhibition in wild-type cells due to OST catalytic subunit redundancy.

Cell Proliferation Assay

Cell Line: Parental PC9 EGFR mutant non-small cell lung cancer (NSCLC) cells, PC9-CD8-EGFR-CL (N-glycosylation-independent EGFR) cells
Concentration: 5 μM
Incubation Time: 5 days
Result: Reduced proliferation of parental PC9 cells by approximately 70%.
Showed significantly rescued proliferation of PC9-CD8-EGFR-CL cells relative to parental cells, confirming the anti-proliferative effect is mediated via inhibition of EGFR N-glycosylation.

Western Blot Analysis

Cell Line: PC9 EGFR mutant NSCLC cells
Concentration: 1 μM, 5 μM
Incubation Time: 24 h
Result: Caused dose-dependent inhibition of EGFR Y1068 phosphorylation, accompanied by reduced phosphorylation of AKT S473, p70 S6K T389, and S6RP S235-236.
Induced increased levels of the pro-apoptotic protein Bim at both tested concentrations.

Cell Cycle Analysis

Cell Line: PC9 EGFR mutant NSCLC cells
Concentration: 5 μM
Incubation Time: 24 h
Result: Induced a greater accumulation of PC9 cells in the G1 phase of the cell cycle compared to vehicle control, indicating G1 cell cycle arrest.

Western Blot Analysis

Cell Line: H3255 (EGFR L858R), HCC-4006 (EGFR del747-749, A750P), and HCC-2935 (EGFR del746-751, S752I) EGFR mutant NSCLC cells
Concentration: 5 μM
Incubation Time: 24 h
Result: Inhibited EGFR Y1068 phosphorylation, reduced phosphorylation of AKT S473, p70 S6K T389, and S6RP S235-236, and induced increased levels of Bim in all three EGFR mutant NSCLC cell lines.

Cell Cycle Analysis

Cell Line: H3255 and HCC-2935 EGFR mutant NSCLC cells
Concentration: 5 μM
Incubation Time: 24 h
Result: Induced a modest increase in G1 cell cycle arrest and a significant increase in the sub-G1 populationl, indicating induction of cell death.

Western Blot Analysis

Cell Line: H1975-OR (osimertinib-resistant, EGFR L858R/T790M) and HCC827-GR (gefitinib-resistant, EGFR del19/MET-amplified) NSCLC cells
Concentration: 10 μM
Incubation Time: 24 h
Result: Reduced PTK7 N-glycosylation and inhibited STAT3 Y705 phosphorylation in H1975-OR cells.
Reduced PTK7 and MET N-glycosylation and inhibited STAT3 Y705 phosphorylation in HCC827-GR cells.
体内研究
(In Vivo)

NGI-189 (10 mg/kg;腹腔注射;每 2 天 1 次;共给药 8 次) 可在携带 EGFR 突变的非小细胞肺癌 PDX 模型,以及 Gefitinib 耐药的 HCC827-GR 非小细胞肺癌异种移植模型中显著延缓肿瘤生长。
NGI-189 (10 mg/kg;腹腔注射;每两天一次) 在 Osimertinib 耐药的 H1975-OR 非小细胞肺癌异种移植物中诱导显著的肿瘤消退。
NGI-189 (10 mg/kg;腹腔注射;每隔 1 天给药 1 次;共给药 3 次) 在小鼠体内具有良好的耐受性,血液检测或器官组织病理学检查均未发现明显毒性。

Animal Model: NSG mice (female, 6-8 weeks old, immunodeficient)
Dosage: 10 mg/kg
Administration: i.p.; every other day; 8 total doses
Result: Kept tumor volume at 193 mm3 by Day 8, while vehicle-treated tumors grew to 450 mm3.
Doubled the time for tumors to reach 500 mm3.
Reduced EGFR protein levels in tumors.
Showed weight changes similar to vehicle-treated mice.\nKept tumor volume at 167 mm3 by Day 12, while vehicle-treated tumors grew to 414 mm3.
Doubled the time for tumors to reach 500 mm3.
Showed significantly higher body weight at the end of treatment compared to vehicle controls.
Animal Model: athymic Swiss nu/nu mice (female, 6-8 weeks old)
Dosage: 10 mg/kg
Administration: i.p.; every other day
Result: Induced significant tumor regression.
Achieved 60% of treated mice remaining progression-free at Day 90, compared to 0% of vehicle-treated mice.
Showed weight changes similar to vehicle-treated mice.
Animal Model: athymic Swiss nu/nu mice (female, 6-8 weeks old)
Dosage: 10 mg/kg
Administration: i.p.; every other day; 8 total doses
Result: Limited tumor volume to 400 mm3 by Day 20.
Prolonged the time for tumors to reach 500 mm3.
Showed weight changes similar to vehicle-treated mice.
Animal Model: athymic Swiss nu/nu mice (female, 6-8 weeks old)
Dosage: 10 mg/kg
Administration: i.p.; every other day; 3 total doses
Result: Showed no significant differences from vehicle-treated mice in blood counts, serum chemistries, or organ cytopathology.
Had only minor age-related abnormalities, same as vehicle group.
性状 固体
颜色 White to off-white

化学信息

分子量 478.63
分子式 C22H30N4O4S2
CAS No. 2763063-26-7

储存&溶解度

储存方式
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 6 months
-20°C 1 month
运输条件 Room temperature in continental US; may vary elsewhere.
溶液配制表

DMSO 中的溶解度 : 100 mg/mL (208.93 mM; 超声助溶; 吸湿的 DMSO 对产品的溶解度有显著影响,请使用新开封的 DMSO)

可选溶剂浓度1 mg5 mg10 mg25 mg
DMSO1 mM2.0893 mL10.4465 mL20.8930 mL52.2324 mL
5 mM0.4179 mL2.0893 mL4.1786 mL10.4465 mL
10 mM0.2089 mL1.0446 mL2.0893 mL5.2232 mL
15 mM0.1393 mL0.6964 mL1.3929 mL3.4822 mL
20 mM0.1045 mL0.5223 mL1.0446 mL2.6116 mL
25 mM0.0836 mL0.4179 mL0.8357 mL2.0893 mL
30 mM0.0696 mL0.3482 mL0.6964 mL1.7411 mL
40 mM0.0522 mL0.2612 mL0.5223 mL1.3058 mL
50 mM0.0418 mL0.2089 mL0.4179 mL1.0446 mL
60 mM0.0348 mL0.1741 mL0.3482 mL0.8705 mL
80 mM0.0261 mL0.1306 mL0.2612 mL0.6529 mL
100 mM0.0209 mL0.1045 mL0.2089 mL0.5223 mL

* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。
储备液的保存方式和期限:-80°C, 6 months; -20°C, 1 month。-80°C储存时,请在6个月内使用,-20°C储存时,请在1个月内使用。

该溶液配制表仅适用于固体产品。对于液体产品,请根据标明的浓度或密度计算稀释方案。

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础